Evangelos Terpos to Humans
This is a "connection" page, showing publications Evangelos Terpos has written about Humans.
Connection Strength
0.338
-
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021 08 02; 11(8):138.
Score: 0.008
-
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells. 2021 07 30; 10(8).
Score: 0.008
-
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021 07 01; 137(26):3674-3676.
Score: 0.008
-
Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. Am J Hematol. 2021 08 01; 96(8):896-900.
Score: 0.008
-
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier? Am J Hematol. 2021 09 01; 96(9):E321-E324.
Score: 0.008
-
Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. J Hematol Oncol. 2021 05 31; 14(1):86.
Score: 0.008
-
SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. Eur J Intern Med. 2021 07; 89:87-96.
Score: 0.008
-
Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am J Hematol. 2021 07 01; 96(7):E257-E259.
Score: 0.008
-
Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses. 2020 12 25; 13(1).
Score: 0.007
-
Controversies in the use of new bone-modifying therapies in multiple myeloma. Br J Haematol. 2021 Jun; 193(6):1034-1043.
Score: 0.007
-
Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. N Engl J Med. 2020 10 22; 383(17):1695.
Score: 0.007
-
Hematological findings and complications of COVID-19. Am J Hematol. 2020 07; 95(7):834-847.
Score: 0.007
-
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020 08; 34(8):2000-2011.
Score: 0.007
-
Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis. Hematology. 2019 Dec; 24(1):318-324.
Score: 0.007
-
Screening for Gaucher disease among patients with plasma cell dyscrasias. Leuk Lymphoma. 2021 03; 62(3):761-763.
Score: 0.007
-
Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density. Ann Hematol. 2019 Jul; 98(7):1583-1592.
Score: 0.007
-
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. Int J Cancer. 2019 07 15; 145(2):559-568.
Score: 0.006
-
Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. Hormones (Athens). 2018 Dec; 17(4):573-579.
Score: 0.006
-
Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. Blood Adv. 2018 11 13; 2(21):2837-2847.
Score: 0.006
-
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice. Eur J Haematol. 2018 Oct; 101(4):556-565.
Score: 0.006
-
Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis. Endocrine. 2018 11; 62(2):487-489.
Score: 0.006
-
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018 09; 32(9):1883-1898.
Score: 0.006
-
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Ann Hematol. 2018 Sep; 97(9):1671-1682.
Score: 0.006
-
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. Blood Cancer J. 2018 05 11; 8(5):42.
Score: 0.006
-
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2018 06; 18(6):431-437.
Score: 0.006
-
Going the distance: Are we losing patients along the multiple myeloma treatment pathway? Crit Rev Oncol Hematol. 2018 Jun; 126:19-23.
Score: 0.006
-
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017. Clin Lymphoma Myeloma Leuk. 2018 05; 18(5):321-334.
Score: 0.006
-
Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018 01 12; 8(1):7.
Score: 0.006
-
Biology and treatment of myeloma related bone disease. Metabolism. 2018 03; 80:80-90.
Score: 0.006
-
Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. Eur J Haematol. 2018 Jan; 100(1):10-19.
Score: 0.006
-
Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. Ann Hematol. 2017 Oct; 96(10):1707-1714.
Score: 0.006
-
Increased expression of platelet derived growth factor receptor ß on trephine biopsies correlates with advanced myeloma. J BUON. 2017 Jul-Aug; 22(4):1032-1037.
Score: 0.006
-
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017 07; 178(1):61-71.
Score: 0.006
-
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016. Clin Lymphoma Myeloma Leuk. 2017 06; 17(6):329-339.
Score: 0.006
-
Emerging treatment approaches for myeloma-related bone disease. Expert Rev Hematol. 2017 Mar; 10(3):217-228.
Score: 0.006
-
The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. Am Soc Clin Oncol Educ Book. 2016; 35:e407-17.
Score: 0.005
-
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res. 2010 Mar; 34(3):399-402.
Score: 0.003
-
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma. 2005 Dec; 46(12):1699-707.
Score: 0.003
-
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003 Aug 01; 102(3):1064-9.
Score: 0.002
-
Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med. 2021 08 23; 19(1):208.
Score: 0.002
-
Systemic IL-15, IFN-?, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021 08 10; 36(6):109504.
Score: 0.002
-
Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. J Infect. 2021 07; 83(1):1-16.
Score: 0.002
-
Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays. Sci Rep. 2021 03 23; 11(1):6614.
Score: 0.002
-
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci. 2021 Jan 12; 28(1):9.
Score: 0.002
-
Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece: Indirect victims of the pandemic? Medicine (Baltimore). 2020 Dec 24; 99(52):e23845.
Score: 0.002
-
Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021 May; 21(2):167-179.
Score: 0.002
-
Response of an oncology unit in the midst of the COVID-19 outbreak. J Oncol Pharm Pract. 2020 Dec; 26(8):1947-1952.
Score: 0.002
-
Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. Thromb Haemost. 2020 Dec; 120(12):1680-1690.
Score: 0.002
-
Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020 Nov; 20(4):493-506.
Score: 0.002
-
Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. J Cell Mol Med. 2019 12; 23(12):8010-8018.
Score: 0.002
-
Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. Circ Res. 2019 09 27; 125(8):744-758.
Score: 0.002
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019 06; 20(6):e302-e312.
Score: 0.002
-
A revised international prognostic score system for Waldenström's macroglobulinemia. Leukemia. 2019 11; 33(11):2654-2661.
Score: 0.002
-
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treat Rev. 2019 Jun; 76:57-67.
Score: 0.002
-
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome. Ann Hematol. 2019 Jun; 98(6):1457-1466.
Score: 0.002
-
Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Ann Hematol. 2019 Jun; 98(6):1427-1434.
Score: 0.002
-
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncol. 2019 May; 15(13):1411-1428.
Score: 0.002
-
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid. 2018 Dec; 25(4):234-241.
Score: 0.002
-
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leuk Lymphoma. 2019 03; 60(3):619-628.
Score: 0.002
-
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer J. 2018 11 07; 8(11):102.
Score: 0.002
-
Management of multiple myeloma bone disease: impact of treatment on renal function. Expert Rev Hematol. 2018 11; 11(11):881-888.
Score: 0.002
-
Variation of endothelium-related hemostatic factors during sepsis. Microcirculation. 2018 11; 25(8):e12500.
Score: 0.002
-
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer J. 2018 10 04; 8(10):95.
Score: 0.002
-
GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study. Clin Exp Nephrol. 2019 Feb; 23(2):199-206.
Score: 0.002
-
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018 09; 103(9):1422-1432.
Score: 0.002
-
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):e401-e419.
Score: 0.002
-
Optimizing therapy in bortezomib-exposed patients with multiple myeloma. Expert Rev Hematol. 2018 06; 11(6):463-469.
Score: 0.002
-
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J. 2018 05 24; 8(5):46.
Score: 0.002
-
The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and meta-analysis. Hormones (Athens). 2018 Jun; 17(2):153-166.
Score: 0.002
-
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018 08; 32(8):1697-1712.
Score: 0.002
-
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 2018 03 09; 8(3):31.
Score: 0.002
-
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. J Med Econ. 2018 May; 21(5):525-536.
Score: 0.002
-
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. Expert Rev Hematol. 2018 03; 11(3):219-237.
Score: 0.002
-
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018 03; 19(3):370-381.
Score: 0.002
-
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood. 2018 04 05; 131(14):1568-1575.
Score: 0.002
-
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Sci Rep. 2017 12 19; 7(1):17802.
Score: 0.001
-
Rare manifestations of extramedullary myeloma: testicular plasmacytomas. Leuk Lymphoma. 2018 08; 59(8):2002-2004.
Score: 0.001
-
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018 02; 103(2):197-211.
Score: 0.001
-
Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation. Eur J Haematol. 2018 Feb; 100(2):131-139.
Score: 0.001
-
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018 01 25; 131(4):464-467.
Score: 0.001
-
An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opin Pharmacother. 2017 Dec; 18(17):1883-1897.
Score: 0.001
-
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. Eur J Haematol. 2017 Nov; 99(5):409-414.
Score: 0.001
-
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases. Leuk Lymphoma. 2018 04; 59(4):983-987.
Score: 0.001
-
Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL). J BUON. 2017 Jul-Aug; 22(4):1022-1031.
Score: 0.001
-
Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization. J Bone Miner Metab. 2018 Jul; 36(4):399-409.
Score: 0.001
-
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. Leuk Lymphoma. 2017 Oct; 58(10):2304-2309.
Score: 0.001
-
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. Am J Hematol. 2017 Jul; 92(7):632-639.
Score: 0.001
-
Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. Metabolism. 2017 06; 71:198-201.
Score: 0.001
-
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017 04; 18(4):e206-e217.
Score: 0.001
-
Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opin Drug Saf. 2017 Feb; 16(2):237-245.
Score: 0.001
-
Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. Expert Opin Investig Drugs. 2017 Feb; 26(2):197-205.
Score: 0.001
-
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br J Haematol. 2017 Mar; 176(5):783-795.
Score: 0.001
-
Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. Clin Nephrol. 2016 Jan; 85(1):44-54.
Score: 0.001
-
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point. Haematologica. 2015 Aug; 100(8):e328-30.
Score: 0.001
-
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015 Apr; 90(4):E60-5.
Score: 0.001
-
Hemodynamic markers and subclinical atherosclerosis in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2014 08; 99(8):2704-11.
Score: 0.001
-
How lenalidomide is changing the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol. 2013 Oct; 88 Suppl 1:S23-35.
Score: 0.001
-
Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated. Br J Haematol. 2008 Jul; 142(1):3-10.
Score: 0.001
-
Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma. 2006 Aug; 47(8):1553-6.
Score: 0.001
-
Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol. 2004 Sep; 126(5):736-42.
Score: 0.001
-
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide. Br J Haematol. 2002 Jan; 116(1):155-7.
Score: 0.000